Cargando…

Genes encoding neuropeptide receptors are epigenetic markers in patients with head and neck cancer: a site-specific analysis

Staging and pathological grading systems are useful but imperfect predictors of recurrence in head and neck squamous cell carcinoma (HNSCC). To identify potential prognostic markers, we examined the methylation status of eight neuropeptide receptor gene promoters in 231 head and neck squamous cell c...

Descripción completa

Detalles Bibliográficos
Autores principales: Misawa, Kiyoshi, Imai, Atsushi, Mochizuki, Daiki, Misawa, Yuki, Endo, Shiori, Hosokawa, Seiji, Ishikawa, Ryuji, Mima, Masato, Shinmura, Kazuya, Kanazawa, Takeharu, Mineta, Hiroyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5652708/
https://www.ncbi.nlm.nih.gov/pubmed/29100314
http://dx.doi.org/10.18632/oncotarget.19356
_version_ 1783273109090992128
author Misawa, Kiyoshi
Imai, Atsushi
Mochizuki, Daiki
Misawa, Yuki
Endo, Shiori
Hosokawa, Seiji
Ishikawa, Ryuji
Mima, Masato
Shinmura, Kazuya
Kanazawa, Takeharu
Mineta, Hiroyuki
author_facet Misawa, Kiyoshi
Imai, Atsushi
Mochizuki, Daiki
Misawa, Yuki
Endo, Shiori
Hosokawa, Seiji
Ishikawa, Ryuji
Mima, Masato
Shinmura, Kazuya
Kanazawa, Takeharu
Mineta, Hiroyuki
author_sort Misawa, Kiyoshi
collection PubMed
description Staging and pathological grading systems are useful but imperfect predictors of recurrence in head and neck squamous cell carcinoma (HNSCC). To identify potential prognostic markers, we examined the methylation status of eight neuropeptide receptor gene promoters in 231 head and neck squamous cell carcinomas. The NPFFR1, NPFFR2, HCRTR1, HCRTR2, NPY1R, NPY2R, NPY4R, and NPY5R promoters were methylated in 80.5%, 79.2%, 67.1%, 73.2%, 35.1%, 36.4%, 38.5%, and 35.9% of the samples, respectively. In a multivariate Cox proportional hazards analysis, the odds ratio for recurrence was 2.044 (95% confidence interval [CI], 1.323–3.156; P = 0.001) when the NPY2R promoter was methylated. In patients without lymph node metastasis (n = 100), methylation of NPY2R (compared with methylation of the other seven genes) best correlated with poor disease-free survival (DFS) (odds ratio, 2.492; 95% CI, 1.190–5.215; P = 0.015). In patients with oral cancer (n = 69), methylated NPY1R and NPY2R were independent prognostic factors for poor DFS, both individually and, even more so, in combination (odds ratio, 3.90; 95% CI, 1.523–9.991; P = 0.005). Similar findings were observed for NPY2R and NPY4R in patients with oropharyngeal cancer (n = 162) (odds ratio, 5.663; 95% CI, 1.507–21.28; P = 0.010).
format Online
Article
Text
id pubmed-5652708
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-56527082017-11-02 Genes encoding neuropeptide receptors are epigenetic markers in patients with head and neck cancer: a site-specific analysis Misawa, Kiyoshi Imai, Atsushi Mochizuki, Daiki Misawa, Yuki Endo, Shiori Hosokawa, Seiji Ishikawa, Ryuji Mima, Masato Shinmura, Kazuya Kanazawa, Takeharu Mineta, Hiroyuki Oncotarget Research Paper Staging and pathological grading systems are useful but imperfect predictors of recurrence in head and neck squamous cell carcinoma (HNSCC). To identify potential prognostic markers, we examined the methylation status of eight neuropeptide receptor gene promoters in 231 head and neck squamous cell carcinomas. The NPFFR1, NPFFR2, HCRTR1, HCRTR2, NPY1R, NPY2R, NPY4R, and NPY5R promoters were methylated in 80.5%, 79.2%, 67.1%, 73.2%, 35.1%, 36.4%, 38.5%, and 35.9% of the samples, respectively. In a multivariate Cox proportional hazards analysis, the odds ratio for recurrence was 2.044 (95% confidence interval [CI], 1.323–3.156; P = 0.001) when the NPY2R promoter was methylated. In patients without lymph node metastasis (n = 100), methylation of NPY2R (compared with methylation of the other seven genes) best correlated with poor disease-free survival (DFS) (odds ratio, 2.492; 95% CI, 1.190–5.215; P = 0.015). In patients with oral cancer (n = 69), methylated NPY1R and NPY2R were independent prognostic factors for poor DFS, both individually and, even more so, in combination (odds ratio, 3.90; 95% CI, 1.523–9.991; P = 0.005). Similar findings were observed for NPY2R and NPY4R in patients with oropharyngeal cancer (n = 162) (odds ratio, 5.663; 95% CI, 1.507–21.28; P = 0.010). Impact Journals LLC 2017-07-18 /pmc/articles/PMC5652708/ /pubmed/29100314 http://dx.doi.org/10.18632/oncotarget.19356 Text en copyright: © 2017 Misawa et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (http://creativecommons.org/licenses/by/3.0/) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Misawa, Kiyoshi
Imai, Atsushi
Mochizuki, Daiki
Misawa, Yuki
Endo, Shiori
Hosokawa, Seiji
Ishikawa, Ryuji
Mima, Masato
Shinmura, Kazuya
Kanazawa, Takeharu
Mineta, Hiroyuki
Genes encoding neuropeptide receptors are epigenetic markers in patients with head and neck cancer: a site-specific analysis
title Genes encoding neuropeptide receptors are epigenetic markers in patients with head and neck cancer: a site-specific analysis
title_full Genes encoding neuropeptide receptors are epigenetic markers in patients with head and neck cancer: a site-specific analysis
title_fullStr Genes encoding neuropeptide receptors are epigenetic markers in patients with head and neck cancer: a site-specific analysis
title_full_unstemmed Genes encoding neuropeptide receptors are epigenetic markers in patients with head and neck cancer: a site-specific analysis
title_short Genes encoding neuropeptide receptors are epigenetic markers in patients with head and neck cancer: a site-specific analysis
title_sort genes encoding neuropeptide receptors are epigenetic markers in patients with head and neck cancer: a site-specific analysis
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5652708/
https://www.ncbi.nlm.nih.gov/pubmed/29100314
http://dx.doi.org/10.18632/oncotarget.19356
work_keys_str_mv AT misawakiyoshi genesencodingneuropeptidereceptorsareepigeneticmarkersinpatientswithheadandneckcancerasitespecificanalysis
AT imaiatsushi genesencodingneuropeptidereceptorsareepigeneticmarkersinpatientswithheadandneckcancerasitespecificanalysis
AT mochizukidaiki genesencodingneuropeptidereceptorsareepigeneticmarkersinpatientswithheadandneckcancerasitespecificanalysis
AT misawayuki genesencodingneuropeptidereceptorsareepigeneticmarkersinpatientswithheadandneckcancerasitespecificanalysis
AT endoshiori genesencodingneuropeptidereceptorsareepigeneticmarkersinpatientswithheadandneckcancerasitespecificanalysis
AT hosokawaseiji genesencodingneuropeptidereceptorsareepigeneticmarkersinpatientswithheadandneckcancerasitespecificanalysis
AT ishikawaryuji genesencodingneuropeptidereceptorsareepigeneticmarkersinpatientswithheadandneckcancerasitespecificanalysis
AT mimamasato genesencodingneuropeptidereceptorsareepigeneticmarkersinpatientswithheadandneckcancerasitespecificanalysis
AT shinmurakazuya genesencodingneuropeptidereceptorsareepigeneticmarkersinpatientswithheadandneckcancerasitespecificanalysis
AT kanazawatakeharu genesencodingneuropeptidereceptorsareepigeneticmarkersinpatientswithheadandneckcancerasitespecificanalysis
AT minetahiroyuki genesencodingneuropeptidereceptorsareepigeneticmarkersinpatientswithheadandneckcancerasitespecificanalysis